Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company ...
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Wilmette, Illinois, founded in 2014 by Dr. Chandler D. Robinson, who serves as CEO. The company is dedicated to developing proprietary therapeutics for cancer patients and addressing rare diseases. Its primary focus is on oncology, with a pipeline centered on ...Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Wilmette, Illinois, founded in 2014 by Dr. Chandler D. Robinson, who serves as CEO. The company is dedicated to developing proprietary therapeutics for cancer patients and addressing rare diseases. Its primary focus is on oncology, with a pipeline centered on radiopharmaceuticals. Key product candidates include ALXN1840, a late-stage oral therapy for Wilson disease (licensed from Alexion), and MNPR-101, a humanized monoclonal antibody conjugated to various radioisotopes (such as actinium-225 and zirconium-89) for treating advanced solid tumors expressing urokinase plasminogen activator receptor. The company also collaborates with NorthStar to develop radio-immuno-therapeutics for severe COVID-19 and with Excel Diagnostics for imaging and therapeutic agents. Financially, Monopar has a market cap of approximately $798.6 million, with no revenue (clinical-stage), and operates with a lean team of around 22 employees (11-50 range). The company is listed on NASDAQ and has a high current ratio of 56.0, indicating strong liquidity, but negative profitability metrics due to R&D investments. Key financial metrics include an EV/EBITDA of -47.7 and a price-to-book of 7.5, reflecting investor expectations for future growth. The company's long-term vision is to bring novel radiopharmaceuticals to market, leveraging its expertise in targeted alpha therapy and its partnerships to advance its pipeline through clinical trials.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-13.7M
+12.0%
-36.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-12.2M
-90.5%
-93380.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.1%
—
-15.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
51.35x
+347.5%
-40.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
